Current oncology最新文献

{"title":"Merkel-Cell Carcinoma: Local Recurrence Rate Versus Radiation Dose Study from a 949-Patient Database.","authors":"Patricia Tai, Michael Veness, Vimal H Prajapati, Aoife Jones Thachuthara, Jidong Lian, Avi Assouline, Edward Yu, Kurian Joseph","doi":"10.3390/curroncol32040202","DOIUrl":"https://doi.org/10.3390/curroncol32040202","url":null,"abstract":"<p><p>(1) Background: Knowledge regarding the optimal radiotherapy dose for Merkel-cell carcinoma (MCC) remains limited. (2) Methods: Following a PubMed search, equivalent doses in 2 Gy fractions (Gy2) were compared. (3) Results: Of the 949 patients, 939 were evaluable, with 728 (77.5%) cases localized to the primary site and 171 irradiated without chemotherapy. The overall local recurrence rate (LRR) was 23% (40/171). After definitive radiotherapy with EQD2 < 50 Gy2 versus ≥50 Gy2, the LRRs were 23.1% (3/13) and 12.5% a(1/8), respectively (<i>p</i> = 0.0004). (4) Conclusions: For definitive radiotherapy, EQD2 < 50 Gy2 demonstrates a significantly higher LRR than ≥50 Gy2 (<i>p</i> = 0.0004). This study is clinically useful and unique with stratification by definitive/adjuvant settings and positive/negative resection margins. A future prospective multicenter study is needed to determine the optimal radiotherapy doses.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 4","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12026359/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143967941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Equivalent Disease-Specific Survival Between Rural and Urban Osteosarcoma Patients: A Retrospective Analysis of the SEER Database.","authors":"Kate S Woods, Mitchell A Taylor, Peter T Silberstein","doi":"10.3390/curroncol32040199","DOIUrl":"https://doi.org/10.3390/curroncol32040199","url":null,"abstract":"<p><p>Osteosarcoma is the most common primary malignancy of bone. Previous studies have demonstrated rural-urban disparities in metastatic disease incidence and overall survival in high-grade osteosarcoma patients. However, there is a paucity of literature investigating disease-specific survival (DSS) disparities between rural and urban patients, which is explored herein using the SEER database. Patients with biopsy-proven cases of osteosarcoma were identified from 2000-2021. Statistical analysis was completed using SPSS version 29.0.2 and included chi-squared, Kaplan-Meier and log-rank, and stepwise Cox regressions. Statistical significance was considered at <i>p</i> < 0.05. Kaplan-Meier analysis revealed no significant differences in 5- and 10-year DSS between rural (55.0% and 47.0%) and urban patients (56.0% and 51.0%) (<i>p</i> = 0.107). Multivariable analysis further revealed no significant DSS difference between rural and urban patients (aHR: 1.03; 95% CI: 0.86-1.24; <i>p</i> = 0.757). This study expands upon prior research by investigating DSS between rural and urban osteosarcoma patients and finding no significant differences. While rural living is often associated with worse outcomes, important prognostic factors for osteosarcoma, including metastatic disease at presentation and tumor grade, were not significantly different between rural and urban patients in our study, possibly explaining our DSS-related findings. Factors other than geographical location likely impact outcomes, and future research should examine other ways that rural living may influence cancer care.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 4","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12025863/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143972504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidence Rates of Cutaneous Immune-Related Adverse Events in Patients with Lung Cancer: A Systematic Review and Meta-Analysis.","authors":"Zhihui Yang, Yuanyuan Luo, Ruiqi Lu, Xinqi Liu, Hanyu Liu, Suting Liu, Chen Huang, Jinhui Tian, Lili Zhang","doi":"10.3390/curroncol32040195","DOIUrl":"https://doi.org/10.3390/curroncol32040195","url":null,"abstract":"<p><strong>Objective: </strong>Cutaneous immune-related adverse events (cirAEs) represent a prevalent manifestation of adverse reactions linked to immune checkpoint inhibitors (ICIs) therapy, substantially affecting patients' quality of life. This systematic review and meta-analysis aimed to quantify the pooled incidence of cirAEs in this population and strengthen clinical awareness for early recognition and management.</p><p><strong>Methods: </strong>A comprehensive search of PubMed, Embase, CINAHL, Cochrane Library, CBM, CNKI, and Wanfang databases was conducted from inception to December 2022. Literature that reported the incidence of cirAEs in patients with lung cancer receiving ICIs therapy was included. A meta-analysis was conducted using R software, version 4.4.1 to estimate the pooled incidence of cirAEs, and a random-effects model was used for data synthesis. Begg's rank correlation and funnel plots were used to assess publication bias.</p><p><strong>Results: </strong>A total of 99 articles involving 23,814 patients with lung cancer receiving ICIs therapy were included, with publication dates ranging from 2012 to 2022. The meta-analysis results reveal that the incidence of cirAEs in patients with lung cancer was 20.26% (95% confidence interval [CI (17.12-23.81)]. Significant differences were observed between all subgroups, including continent, study type, combination therapy, dual ICIs therapy, and diagnostic criteria for cirAEs for Grade 1-2 and Grade 3-4 incidences.</p><p><strong>Conclusions: </strong>The incidence of cirAEs in patients with lung cancer is relatively high, particularly undergoing combined or dual ICIs therapy. To comprehensively characterize cirAEs in patients with lung cancer, large-scale multicenter studies integrating real-world pharmacovigilance data are warranted to establish precise incidence estimates and identify clinically significant risk factors.</p><p><strong>Implications for clinical practice: </strong>This review's insights aroused clinical staff's attention and concern about cirAEs, potentially enhancing the quality of life of patients with cancer.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 4","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12025845/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143973087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Construction of a Nomogram Model for Predicting Pathologic Complete Response in Breast Cancer Neoadjuvant Chemotherapy Based on the Pan-Immune Inflammation Value.","authors":"Zhuowan Tian, Yiqing Xi, Mengting Chen, Meishun Hu, Fangfang Chen, Lei Wei, Jingwei Zhang","doi":"10.3390/curroncol32040194","DOIUrl":"10.3390/curroncol32040194","url":null,"abstract":"<p><strong>Background: </strong>The pan-immune inflammation value (PIV) has unclear predictive utility for pathologic complete response (pCR) in breast cancer patients undergoing neoadjuvant chemotherapy (NAC). This study aimed to evaluate the PIV's predictive value and develop a nomogram integrating PIV for individualized pCR prediction.</p><p><strong>Methods: </strong>In a retrospective multicenter study of 507 NAC-treated patients (training cohort: 357; validation cohort: 150), independent predictors of pCR were identified through univariate and multivariate logistic regression. A nomogram was constructed and validated using receiver operating characteristic (ROC) curves, calibration curves, and decision curve analysis (DCA). Net reclassification improvement (NRI) and integrated discrimination improvement (IDI) evaluated the improvement in performance after incorporating the PIV indicator.</p><p><strong>Results: </strong>The high PIV patients (cutoff: 316.533) had significantly lower pCR rates than the low PIV patients (<i>p</i> < 0.001). The nomogram incorporating PIV, estrogen receptor (ER), human epidermal growth factor receptor-2 (Her2), tumor diameter, clinical node stage, and chemotherapy regimen showed excellent discrimination (training cohort area under the curve (AUC): 0.861, 95% confidence interval (CI): 0.821-0.901; validation cohort AUC: 0.815, 95% CI: 0.748-0.882). The calibration curves demonstrate high prediction accuracy (Hosmer-Lemeshow test: <i>p</i> > 0.05), while DCA, NRI (0.341, 95% CI: 0.181-0.500), and IDI (0.017, 95% CI: 0.004-0.029) confirm clinical utility.</p><p><strong>Conclusions: </strong>The PIV is an independent predictor of pCR, and the PIV-based nomogram provides a reliable tool for optimizing NAC response prediction in breast cancer.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 4","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12026318/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143968801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"How Can We Engage Oncology Care Providers and Glioblastoma Patients in Conversations About Physical Activity: A Qualitative Descriptive Study Using the Theoretical Domains Framework.","authors":"Jodi E Langley, Grace Warner, Christine Cassidy, Robin Urquhart, Mary MacNeil, Melanie R Keats","doi":"10.3390/curroncol32040197","DOIUrl":"https://doi.org/10.3390/curroncol32040197","url":null,"abstract":"<p><p>Glioblastoma (GB) is the most common primary malignant brain tumour in adults. Physical activity (PA) has value as a supportive service for individuals living with a GB diagnosis to help maintain quality of life and physical functioning. The objective of this study is to understand how oncology care providers (OCPs), family/friend caregivers, and health system decision makers can include conversations of PA into care for those living with a GB. We conducted 19 semi-structured interviews guided by the Capability, Opportunity, Motivation-Behaviour (COM-B) model and further refined them by the theoretical domains framework (TDF). The data were then analyzed using a directed content analysis using a codebook generated using the TDF. Patients and family/friend caregivers appreciated hearing about PA from their OCPs, from initial diagnosis into follow-up appointments, and they saw PA as a way to take a break from cancer/medically focused care, and historical PA behaviours did not mean patients were more or less likely to be open about PA discussions. This study further emphasises the inclusion of PA discussions in clinical care. OCPs in GB care feel they have the knowledge to partake in PA conversations, and GB patients are open to having these conversations. However, specific barriers are in place that do not lead to widespread implementation of PA discussions for all patients.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 4","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12026007/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143973085","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is There (Still) a Place for Sequential Conditioning?","authors":"Boris Bours, Stavroula Masouridi-Levrat","doi":"10.3390/curroncol32040196","DOIUrl":"https://doi.org/10.3390/curroncol32040196","url":null,"abstract":"<p><p>There is still an unmet need for the treatment of high-risk hematological malignancies. To date, allogeneic stem cell transplantation remains the only chance of cure. Most patients suffering from high-risk hematological malignancies are of an older age and often present with comorbidities. Moreover, patients achieving remission often suffer from early relapse. Amongst the different treatment options, sequential conditioning has yet to prove its value against other conditioning regimens. Sequential conditioning relies on a short course of intensive chemotherapy that is quickly followed by immunosuppressive conditioning before allogeneic stem cell transplantation. Here, we will try to determine which patients can benefit from sequential conditioning. Amongst the different sequential regimens, we will also try to assess if one regimen is better than all the others. Despite the several studies conducted on sequential conditioning, very few are prospective work and head-to-head comparisons are almost inexistant. Sequential conditioning also relies on the use of prophylactic donor lymphocyte infusion post-transplantation. Hence, limiting non-relapse complications is of primary importance to the allow administration of post-transplant treatment. In the era of new targeting therapies, is there still a place for sequential conditioning? Can patients benefit from an association of new therapeutic agents and sequential conditioning?</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 4","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12025471/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143985875","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recurrent Metastatic Basal Cell Carcinomas of the Face in a Patient with Gorlin-Goltz Syndrome.","authors":"Petko Petrov, Dobromira Shopova, Georgi Goranov, Atanaska Dinkova, Nina Stoyanova, Nikolay Yanev","doi":"10.3390/curroncol32040193","DOIUrl":"10.3390/curroncol32040193","url":null,"abstract":"<p><p>Gorlin-Goltz syndrome, also known as nevoid basal cell carcinoma syndrome (NBCCS), is a rare, inherited autosomal dominant disorder primarily caused by mutations in the <i>PTCH1</i> gene, which regulates the Hedgehog signaling pathway. This genetic defect leads to the uncontrolled proliferation of basal cells, resulting in the formation of multiple basal cell carcinomas (BCCs) and odontogenic keratocysts (OKCs). This study aims to present a complex clinical case of a patient with Gorlin-Goltz syndrome who developed multiple recurrent metastatic basal cell carcinomas on the facial region, detailing the multidisciplinary treatment strategies employed and the challenges encountered during the management of the disease. The patient, diagnosed with a pathogenic <i>PTCH1</i> gene mutation, underwent a series of treatment interventions over several years. These included multiple surgical excisions aimed at tumor removal, diverse radiotherapy approaches for residual or inoperable lesions, and systemic targeted therapy with Hedgehog pathway inhibitors to control tumor progression. The recurrent and aggressive nature of the basal cell carcinomas resulted in extensive facial tissue loss, posing significant challenges for radical tumor excision and subsequent reconstructive procedures. Multimodal therapeutic strategies, including Mohs micrographic surgery for precise tumor clearance and targeted systemic therapy with vismodegib, were implemented. However, the aggressive progression of lesions required ongoing surgical interventions, highlighting the limitations of current treatment modalities in achieving long-term disease control. This case underscores the critical need for a comprehensive, multidisciplinary approach to managing Gorlin-Goltz syndrome. Successful management requires close collaboration between dermatologists, oncologists, maxillofacial surgeons, and plastic surgeons to balance effective tumor control with optimal functional and aesthetic outcomes. The integration of advanced surgical techniques and targeted molecular therapies shows promise in improving patient outcomes. Nonetheless, early diagnosis, rigorous follow-up, and patient education remain essential components in minimizing disease progression and enhancing the quality of life for affected individuals.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 4","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12025546/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143978289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Prognostic Role of Neutrophil Gelatinase-Associated Lipocalin and Kidney Injury Molecule-1 Expressions in Gastric Carcinomas.","authors":"Duygu Ayaz, Gülden Diniz, Ayşe Gül Pulular, Dudu Solakoğlu Kahraman, Umut Varol, Nuket Özkavruk Eliyatkın, Sevil Sayhan, Ali Kemal Kayapınar","doi":"10.3390/curroncol32040190","DOIUrl":"https://doi.org/10.3390/curroncol32040190","url":null,"abstract":"<p><p><b>Background:</b> The survival rate among stomach adenocarcinoma patients is exceedingly low. NGAL (neutrophil gelatinase-associated lipocalin) has pivotal roles in cell proliferation, immunity, and tumorigenesis. KIM-1 (Kidney Injury Molecule-1), also referred to as TIM-1 and HAVcr-1, is a transmembrane glycoprotein located in healthy immune cells and epithelial cells, and its upregulated form is generally found in several human cancers. <b>Aim:</b> The aim of this study was to investigate the prognostic significance of the expression of KIM-1 and NGAL in stomach cancers and identify NGAL-positive inflammatory cells in the tumor microenvironment. <b>Materials and Methods:</b> We immunohistochemically evaluated the expression of NGAL and KIM1 in 172 cases of stomach adenocarcinomas. <b>Result:</b> The mean age of the patients was 64.07 ± 12.35 years, and the mean and median follow-up period were 25.5 and 20.3 months, respectively. The expression rates of KIM-1 and NGAL in tumor cells were identical at 31.4% (n = 54). In 27 of these cases, both proteins were present. Among the deceased patients, the rate of simultaneous KIM-1 and NGAL positivity was relatively higher (<i>p</i> = 0.041). NGAL-positive inflammatory cells were observed in 13.4% of cases, with no significant correlation between these cells and survival times (<i>p</i> = 0.497). However, there was a negative correlation between survival times and KIM-1 (<i>p</i> = 0.037) and NGAL (<i>p</i> = 0.016) expressions in tumor cells. <b>Conclusions:</b> The present study has shown that KIM-1- and NGAL-positive tumor cells are influential in gastric tumorigenesis. Given the progress in anti-KIM-1 therapy, the presence of KIM-1 expression could contribute to the development of new treatment options for aggressive gastric cancer. However, these discoveries need to be validated in larger-scale studies.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 4","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12026346/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143995070","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Resistance Mutation Profiles Associated with Current Treatments for Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer in the United States: A Systematic Literature Review.","authors":"Pratyusha Vadagam, Dexter Waters, Anil Bhagat, Yuting Kuang, Jennifer Uyei, Julie Vanderpoel","doi":"10.3390/curroncol32040191","DOIUrl":"https://doi.org/10.3390/curroncol32040191","url":null,"abstract":"<p><p>Treatment resistance due to gene alterations remains a challenge for patients with EGFR-mutated advanced or metastatic non-small-cell lung cancer (a/mNSCLC). A systematic literature review (SLR) was conducted to describe resistance mutation profiles and their impact on clinical outcomes in adults with a/mNSCLC in the United States (US). A comprehensive search of MEDLINE and Embase (2018-August 2022) identified 2986 records. Among 45 included studies, osimertinib was the most commonly reported treatment (osimertinib alone: 15 studies; as one of the treatment options: 18 studies), followed by other tyrosine kinase inhibitors (TKIs; 5 studies) and non-TKIs (1 study). For first-line (1L) and second-line (2L) osimertinib, the most frequent EGFR-dependent resistance mechanisms were T790M loss (1L: 15.4%; 2L: 20.5-49%) and C797X mutation (1L: 2.9-12.5%; 2L: 1.4-22%). EGFR-independent mechanisms included MET amplification (1L: 0.6-66%; 2L: 7.2-19%), TP53 mutation (1L: 29.2-33.3%), and CCNE1 amplification (1L: 7.9%; 2L: 10.3%). For patients receiving osimertinib, EGFR T790M mutation loss, EGFR/MET/HER2 amplification, RET fusion, and PIK3CA mutation were associated with worse progression-free survival. Resistance mechanisms resulting from current NSCLC treatments in the US are complex, underscoring the need to address such heterogeneous resistance profiles and improve outcomes for patients with EGFR-mutated a/mNSCLC.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 4","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12025648/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143965025","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"New Therapeutic Scenarios in the Context of Adjuvant Treatment for HR+/HER2-Breast Cancer: The Possible Role of Ribociclib in Treatment Algorithms for Stage II and III.","authors":"Nicola Battelli, Carmela Mocerino, Michele Montedoro, Mirco Pistelli, Ilaria Portarena, Mario Rosanova, Tina Sidoni, Patrizia Vici","doi":"10.3390/curroncol32040192","DOIUrl":"https://doi.org/10.3390/curroncol32040192","url":null,"abstract":"<p><p>Early breast cancer (EBC) treatment has evolved from radical surgery to a multidisciplinary approach, integrating radiotherapy, chemotherapy, targeted therapy, and hormone therapy with surgery to ensure the best possible outcome. Despite these advancements, hormone receptor-positive (HR+)/Human Epidermal Growth Factor Receptor 2-Negative (HER2-) EBC still faces high recurrence rates after endocrine therapy. A panel of oncologists from Central-Southern Italy discussed the profile of ribociclib as an adjuvant therapy, based on the results of the NATALEE study, focusing on efficacy, safety, patient profiles, and regional challenges in treatment access. The experts identified ribociclib as suitable adjuvant treatment for stage II and III HR+/HER2- EBC patients, including those without lymph node involvement but with biologically aggressive disease. In their view, ribociclib could be an interesting option for patients not eligible for chemotherapy due to contraindications. Key challenges in translating the evidence on ribociclib in EBC into clinical practice include treatment duration, patient follow-up, and adverse events management. Strategies to address these challenges range from telemedicine and support from local clinics to tailored communication to improve adherence. Ribociclib is expected to significantly impact adjuvant treatment for HR+/HER2- EBC by addressing broader patient needs and potentially improving long-term outcomes through enhanced adherence and personalized management strategies.</p>","PeriodicalId":11012,"journal":{"name":"Current oncology","volume":"32 4","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12025607/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143973110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}